

ForPatients

by Roche

Unresectable Hepatocellular Carcinoma

A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization

Trial Status
Completed

Trial Runs In
1 Country

Trial Identifier
NCT06503250 ML45337

The information is taken directly from public registry websites such as [ClinicalTrials.gov](https://clinicaltrials.gov), [EuClinicalTrials.eu](https://euclinicaltrials.eu), [ISRCTN.com](https://isrctn.com), etc., and has not been edited.

Official Title:

Effectiveness and Safety of Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization as Conversion Therapy Among Patients With Initially Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice in China

Trial Summary:

This is a multicenter, retrospective, observational cohort study to describe the effectiveness and safety of Atezo+Bev plus Transarterial Chemoembolization (TACE) among adult patients with unresectable hepatocellular carcinoma (HCC) in real-world clinical practice in China. Eligible patients diagnosed with unresectable HCC initiating the Atezo+Bev and TACE between 28 October 2020 and 31 December 2023 will be included in this study.

Hoffmann-La Roche
Sponsor

N/A
Phase

NCT06503250 ML45337
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
#18 Years

Healthy Volunteers
No

Inclusion Criteria:

ForPatients

by Roche

- Initiating both Atezo+Bev and TACE between 28 October 2020 and 31 December 2023 regardless of sequencing, number of doses/cycles, and type of TACE
- At least one dose of Atezo+Bev and one cycle of TACE spaced no longer than 4 weeks
- Diagnosed with HCC and considered as unresectable by any of the below criteria:
- Predicted insufficient future liver remnant volume (FLRV) after liver resection, OR * Predicted unattainable safe negative tumor margin resection, i.e., R0 resection, OR * "Unresectable" directly documented in the medical records

Exclusion Criteria:

- No visit record after initiating both Atezo+Bev and TACE
- Treated with other systemic therapy or resection against HCC
- Diagnosed with concomitant cancer except for basal cell carcinoma
- Advanced portal vein tumor thrombosis (PVTT) as defined by: Grade Vp 4, Cheng's Classification Type III or IV, or presence of a tumor thrombus in the main trunk of the portal vein, a portal vein branch contralateral to the primarily involved lobe, or superior mesenteric vein
- China Liver Cancer (CNLC) Stage IIIb, or history of extrahepatic metastasis
- Terminal-stage HCC